Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Platinum-resistant Ovarian Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 1273Specimen Handling 871Carboplatin 832Magnetic Resonance Spectroscopy 808Cyclophosphamide 803Cisplatin 729Nivolumab 659Paclitaxel 631Radiotherapy 574Gemcitabine 572Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 334Rituximab 333Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 303Ipilimumab 294Standard of Care 293Etoposide 285Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × afuresertib × 1 year × Clear all
NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Laekna Limited

Phase 3 Active not recruiting
256 enrolled
Breast

Breast Neoplasms

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Laekna Limited

Phase 1/2 Completed
22 enrolled
GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡